StonvexLoading…
StonvexStonvexStonvexCore line items from MEDP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $706.60M | $2.53B | $1.82B | $1.16B |
Operating Income | $141.50M | $534.93M | $381.67M | $239.86M |
Net Income | $123.87M | $451.12M | $315.99M | $90.26M |
EPS (Diluted) | $4.28 | $15.28 | $10.64 | $6.79 |
Total Assets | $2.13B | $1.98B | $1.75B | $1.57B |
Total Liabilities | $1.53B | $1.52B | $1.46B | $1.40B |
Cash & Equivalents | $652.68M | $497.05M | $285.35M | $46.33M |
Free Cash Flow OCF − CapEx | $144.97M | $681.87M | $493.75M | $258.25M |
Shares Outstanding | 28.56M | 28.37M | 28.17M | 28.09M |